---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-23-006952"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2023-10-26T23:59:59+00:00"
generated_at: "2026-06-09T08:39:32.204645+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bluejay Diagnostics amends Toray license; royalty cut to 7.5% of net sales, supply deal for FDA path

## Summary
- Royalty rate reduced from 15% to 7.5% of net sales (or less) for 10-year term; 50% reduction after patent expiry.
- New supply agreement: Toray will manufacture intermediates for FDA-approval cartridges through Oct 2025 or FDA clearance.
- Bluejay obtains right to sublicense Toray IP to Sanyoseiko for manufacturing Symphony device and cartridges for clinical trials.
- Technology transfer from Toray to Sanyoseiko for cartridge manufacturing, enabling commercial scale production.
- Prior upfront license fee of $240,000 already paid; post-commercial minimum annual royalty of $100,000.

## SEC filing metadata
- accession: 0001013762-23-006952
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2023-10-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000101376223006952/0001013762-23-006952-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000101376223006952/ea187299-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-23-006952
- JSON: https://secwatch.observer/filing/0001013762-23-006952.json
- Plain text: https://secwatch.observer/filing/0001013762-23-006952.txt

## Key facts
- Material Agreements
  Bluejay Diagnostics, Inc. amended New Toray License Agreement with Toray Industries, Inc. valued at royalty reduced from 15% to 7.5% of net sales (effective 2023-10-23).
  - Action: amendment
  - Agreement: license
  - Counterparty: Toray Industries, Inc.
  - Value: royalty reduced from 15% to 7.5% of net sales
  - Effective: 2023-10-23
  source text: On October 23, 2023, Bluejay Diagnostics, Inc. (the “Company”) and Toray Industries, Inc. (“Toray”) entered into an Amended and Restated License Agreement (the “New Toray License Agreement”) and a Master Supply Agreement (the “New Toray Supply Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1704287/000101376223006952/0001013762-23-006952-index.htm
- Material Agreements
  Bluejay Diagnostics, Inc. amended New Toray Supply Agreement with Toray Industries, Inc. valued at Toray to manufacture near-term product intermediary components for FDA approval, not commercial sale (effective 2023-10-23).
  - Action: amendment
  - Agreement: supply
  - Counterparty: Toray Industries, Inc.
  - Value: Toray to manufacture near-term product intermediary components for FDA approval, not commercial sale
  - Effective: 2023-10-23
  source text: On October 23, 2023, Bluejay Diagnostics, Inc. (the “Company”) and Toray Industries, Inc. (“Toray”) entered into an Amended and Restated License Agreement (the “New Toray License Agreement”) and a Master Supply Agreement (the “New Toray Supply Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1704287/000101376223006952/0001013762-23-006952-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.